Our Pricing

Published on: June 03, 2026

When you buy GLP-1 injections online UK through Cured Pharmacy, you access the same prescription-strength treatments used in NHS weight management programmes, with transparent pricing from £135.00 and a free clinical assessment completed in under three minutes. Our UK-registered prescribers evaluate your suitability for tirzepatide, semaglutide, or liraglutide based on your medical history, BMI, and weight loss goals.

What Are GLP-1 Injections and How Do They Work?

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of injectable medications originally developed for type 2 diabetes management, now licensed by the MHRA for chronic weight management in adults with obesity or overweight with weight-related health conditions [1]. These medications mimic a natural gut hormone that regulates appetite, slows gastric emptying, and enhances insulin secretion when blood glucose rises.

The mechanism differs significantly from older weight loss tablets like orlistat. Rather than blocking fat absorption, GLP-1 injections work centrally in the brain's appetite centres to reduce hunger signals and increase satiety after smaller meals [1]. Clinical trials consistently demonstrate that patients feel fuller sooner, experience fewer food cravings, and naturally reduce caloric intake without the conscious restriction required by traditional dieting.

At Cured Pharmacy, we stock three licensed GLP-1 formulations: tirzepatide (Mounjaro), semaglutide (Wegovy), and liraglutide (Saxenda). Each has distinct pharmacological properties, dosing schedules, and efficacy profiles that our prescribers match to individual patient needs during the online consultation.

Mounjaro (Tirzepatide): The Dual-Action GLP-1 Injection

Mounjaro represents the newest generation of weight loss injections available in the UK, containing tirzepatide — the first dual GIP/GLP-1 receptor agonist licensed for chronic weight management [2]. Unlike single-pathway medications, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, producing enhanced metabolic effects and greater weight reduction.

In the landmark SURMOUNT-1 trial involving 2,539 adults with obesity, participants receiving the highest tirzepatide dose achieved an average 22.5% body weight reduction over 72 weeks — significantly exceeding results from semaglutide trials [2]. More than half of participants lost at least 20% of their starting weight, a threshold rarely achieved with lifestyle modification alone.

Mounjaro is administered as a once-weekly subcutaneous injection using a pre-filled KwikPen device. Treatment begins at 2.5 mg weekly, with gradual dose escalation every four weeks to minimise gastrointestinal side effects. Our prescribers determine your maintenance dose based on tolerance and weight loss response, with options up to 15 mg weekly for eligible patients.

Mounjaro Pricing and Availability at Cured Pharmacy

Cured Pharmacy supplies genuine UK-licensed Mounjaro KwikPens from £135.00 per month, subject to your prescribed dose following clinical assessment. All pricing is transparent before you complete the consultation, with no hidden fees or subscription commitments. Your first prescription includes comprehensive injection technique guidance and ongoing support from our UK pharmacy team led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073).

Wegovy (Semaglutide): Proven Weekly GLP-1 Treatment

Wegovy contains semaglutide, a selective GLP-1 receptor agonist with extensive clinical evidence for weight management. The STEP trial programme enrolled over 4,500 participants across multiple studies, demonstrating average weight loss of 14.9% over 68 weeks in adults without diabetes [3]. Wegovy received MHRA approval for chronic weight management in 2022 and is recommended by NICE for specific patient populations.

Semaglutide's once-weekly dosing schedule offers convenience comparable to Mounjaro, though the mechanism differs. As a pure GLP-1 agonist without GIP activity, Wegovy produces slightly lower average weight reduction than tirzepatide but maintains an excellent safety profile with well-characterised side effects [3]. Many patients find semaglutide better tolerated during initial dose escalation, making it a suitable first-line option for GLP-1-naïve individuals.

Treatment starts at 0.25 mg weekly, increasing gradually to a maintenance dose of 2.4 mg over 16-20 weeks. Our prescribers may recommend Wegovy over Mounjaro based on your medical history, previous medication responses, or specific clinical considerations identified during your consultation.

Saxenda (Liraglutide): Daily GLP-1 Injection Option

Saxenda offers an alternative for patients who prefer daily dosing or have contraindications to weekly GLP-1 formulations. Liraglutide was the first GLP-1 receptor agonist licensed specifically for weight management in the UK, with a robust evidence base spanning over a decade of clinical use [4]. The daily injection schedule provides steady-state drug levels, which some patients find produces more consistent appetite suppression throughout the day.

In the SCALE trial programme, adults receiving liraglutide 3.0 mg daily achieved average weight loss of 8.4 kg (approximately 8% of body weight) over 56 weeks, compared to 2.8 kg in the placebo group [4]. While absolute weight reduction is lower than weekly GLP-1 formulations, Saxenda remains an effective option for patients seeking modest weight loss or those with specific medical considerations favouring daily administration.

The Saxenda pen delivers doses from 0.6 mg up to 3.0 mg daily. Most patients reach the full 3.0 mg maintenance dose within five weeks. Daily injections require more frequent administration than Mounjaro or Wegovy, but the lower per-injection cost makes Saxenda accessible for budget-conscious patients, starting from £135.00 at Cured Pharmacy.

Who Is Suitable for Saxenda Treatment?

Saxenda is licensed for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea. Our prescribers assess your eligibility during the online consultation, considering your weight loss history, current medications, and treatment preferences. Saxenda may be particularly suitable if you've previously used daily injectable medications or prefer gradual dose titration.

Comparing GLP-1 Injections: Which Treatment Is Right for You?

Choosing between Mounjaro, Wegovy, and Saxenda depends on multiple clinical factors that our prescribers evaluate during your consultation. While all three medications work through GLP-1 receptor activation, differences in potency, dosing frequency, side effect profiles, and cost influence treatment selection for individual patients.

Tirzepatide (Mounjaro) generally produces the greatest average weight loss due to its dual GIP/GLP-1 mechanism, making it the preferred option for patients seeking maximum efficacy and willing to invest in premium treatment. Semaglutide (Wegovy) offers excellent results with once-weekly convenience at a mid-range price point, suitable for most patients new to GLP-1 therapy. Liraglutide (Saxenda) provides daily dosing flexibility and the lowest entry price, ideal for patients preferring steady-state drug levels or requiring more gradual titration.

Beyond efficacy and cost, prescribers consider your medical history, including any history of pancreatitis, thyroid disease, or diabetic retinopathy. Certain conditions may favour one GLP-1 formulation over others. Your prescriber will also discuss realistic expectations — while clinical trials show impressive average results, individual responses vary, and all GLP-1 treatments require commitment to dietary modification and increased physical activity for optimal outcomes.

How to Buy GLP-1 Injections Online UK Through Cured Pharmacy

Our streamlined prescription service makes accessing GLP-1 injections straightforward and fully compliant with UK pharmacy regulations. Start by completing a free online consultation that takes under three minutes — you'll answer questions about your weight history, current medications, relevant medical conditions, and weight loss goals. This information is reviewed by a UK-registered prescriber (doctor or independent prescriber) who determines whether GLP-1 treatment is safe and appropriate for you.

If approved, your prescription is sent electronically to our GPhC-registered pharmacy (registration number 9012511) where Superintendent Pharmacist Tarun Kumar and our dispensing team prepare your medication. We supply only genuine UK-licensed medicines sourced through authorised wholesalers — never grey-market imports or unlicensed formulations. Your GLP-1 injections are dispatched in discreet, unbranded packaging with Royal Mail or courier delivery, typically arriving within 1-3 working days.

After your first prescription, we provide ongoing support including injection technique videos, side effect management guidance, and easy prescription renewals through your online account. Many patients continue GLP-1 treatment for 12-24 months to achieve and maintain their target weight loss, with regular prescriber reviews ensuring treatment remains appropriate as your weight decreases and health improves.

What Happens If GLP-1 Treatment Isn't Suitable for Me?

Not all patients meet the clinical criteria for GLP-1 injections, and our prescribers may recommend alternative weight loss treatments based on your consultation responses. Cured Pharmacy stocks several non-injectable options including orlistat (a lipase inhibitor that reduces fat absorption) and Mysimba (a combination medication affecting appetite centres). If your BMI falls below the threshold for prescription weight loss medication, our prescribers provide evidence-based lifestyle guidance and may suggest reassessment after a period of dietary modification and exercise.

Scientific References

1. Müller, T. D., et al. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72-130. https://doi.org/10.1016/j.molmet.2019.09.010 [accessed 13 August 2026]
2. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205-216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
3. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
4. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11-22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment, dietary modification, and lifestyle factors. GLP-1 receptor agonists are not suitable for everyone and may cause side effects. Your prescriber will discuss risks and benefits during consultation.